(secondQuint)Bevacizumab Versus Ranibizumab in Age Related Macular Degeneration.

 We conducted a retrospective study of 500 eyes with choroidal neovascularization secondary to age-related macular degeneration who were treated with at least two (initial and one month after) intravitreal injection of 1.

25 mg bevacizumab or 0.

5 mg ranibizumab and had a follow-up of at least 3 months.

 Patients underwent Snellen visual acuity testing, optical coherence tomography (OCT) imaging and ophthalmoscopic examination at baseline and follow-up visits.

.

 Bevacizumab Versus Ranibizumab in Age Related Macular Degeneration@highlight

To report the short term anatomic and visual acuity response after intravitreal injection of bevacizumab and ranibizumab in patients with choroidal neovascularization secondary to age-related macular degeneration.

